From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
μopioidreceptor agonist 3 (compound 20) is a potent μopioidreceptor (µOR) agonist with an EC50 of 0.87 nM. μopioidreceptor agonist 3 has the potential for pain and neuropsychiatric indications research .
μopioidreceptor agonist 2 (Compound H-3)is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MORreceptor agonist and can be used for the research of pain and pain related diseases .
μopioidreceptor agonist 1 (Compound H-1a)is an optically pure oxaspiro ring substituted pyrrolopyrazole derivative, acts as a MORreceptor agonist and can be used for the research of pain and pain related diseases .
Muopioidreceptor antagonist 4 (compound 31) is a potent and selective μopioidreceptor (MOR) antagonist with a Ki of 0.38 nM and an EC50 of 1.07 nM. Muopioidreceptor antagonist 4 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Muopioidreceptor antagonist 4 Muopioidreceptor antagonist 4 can be used for researching opioid use disorders (OUD) .
Muopioidreceptor antagonist 3 (compound 26) is a potent and selective μopioidreceptor (MOR) antagonist with a Ki of 0.24 nM and an EC50 of 0.54 nM. Muopioidreceptor antagonist 3 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Muopioidreceptor antagonist 3 can be used for researching opioid use disorders (OUD) .
Muopioidreceptor antagonist 5 (compound NAP) is a selective and blood-brain barrier (BBB) penetrant μopioidreceptor (MOR) antagonist with an EC50 value of 1.14 nM and a Ki value of 0.37 nM. Muopioidreceptor antagonist 5 can be used for researching opioid use disorders (OUD) .
Muopioidreceptor antagonist 2 (compound 25) is a potent, selective and blood-brain barrier (BBB) penetrant μopioidreceptor (MOR) antagonist with a Ki of 0.37 nM and an EC50 of 0.44 nM. Muopioidreceptor antagonist 2 has remarkable CNS antagonism against morphine, and precipitated fewer withdrawal symptoms than Naloxone. Muopioidreceptor antagonist 2 can be used for researching opioid use disorders (OUD) .
σ1 Receptor/μOpioidreceptor modulator 1 (Compound 44) is a potent σ1 receptor antagonist and μopioidreceptor agonist with Kis of 1.86 nM and 2.1 nM, respectively.σ1 Receptor/μOpioidreceptor modulator 1 exhibits potent analgesic activity. σ1 Receptor/μOpioidreceptor modulator 1 can be used for the research of neuropathic pain .
Muopioidreceptor antagonist 1 (compound 19) is a selective and orally active μopioidreceptor (MOR) ligand with an Ki value of 0.58 nM and an EC50 of 1.15 nM. Orally administrating with Muopioidreceptor antagonist 1 increases intestinal motility during morphine-induced constipation. Muopioidreceptor antagonist 1 can be used for researching opioid-induced constipation (OIC) .
Muopioidreceptor antagonist 7 (compound 24) is a potent and CNS permeable antagonist of µOR (µ-opioidreceptor), with an IC50 of 29 ± 3.0 nM. Muopioidreceptor antagonist 7 can be used for the research of pain and opioid use disorder .
μ/κ/δ opioidreceptor agonist 1 is a μopioidreceptor (MOR), κ opioidreceptor (KOR), and δ opioidreceptor (DOR) agonist. μ/κ/δ opioidreceptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .
Acetalin-1 (Ac-RFMWMK-NH2), a hexapeptide, is a μopioidreceptor antagonist with high affinity for μ and κ3 opioidreceptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .
PL-017 is a potent and selective μopioidreceptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 produces long-lasting, reversible analgesia in rats .
PL-017 TFA is a potent and selective μopioidreceptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats .
Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioidreceptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
Samidorphan (ALKS-33) is an orally active opioid system modulator that has a high affinity for binding with μ‐opioid, κ‐opioid, and δ‐opioidreceptors. Samidorphan acts as an antagonist at μ‐opioidreceptors and acts as a partial agonist at k-opioid and δ‐opioidreceptors. Samidorphan primarily acts as an opioidreceptor antagonist in vivo .
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioidreceptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation .
NAQ is a potent and selective μopioidreceptor partial agonist, with a Ki of 0.55 nM. NAQ shows selectivity for Muopioidreceptor over the δ receptor (Ki=132.50 nM) and the κ receptor (Ki=26.45 nM). NAQ can be used for the research of opioid withdrawal or dependence .
Acetalin-3 (Ac-RFMWMT-NH2), a hexapeptide, is a μopioidreceptor antagonist with high affinity for μ and κ3 opioidreceptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .
Naloxegol-d5 (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioidreceptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].
Clocinnamox (mesylate) is a potent opioid antagonist acting at mu, kappa and delta-receptors. Clocinnamox is a selective mu-receptor antagonist than kappa and delta-receptors .
Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible μ-opioidreceptor antagonist, with an IC50 of 1.7 nM. Alvimopan has selectivity for μ-opioidreceptor (Ki=0.47 nM) over κ- and δ-opioidreceptors (Kis=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus .
Alvimopan monohydrate (ADL 8-2698 monohydrate) is a potent, selective, orally active and reversible μ-opioidreceptor antagonist, with an IC50 of 1.7 nM. Alvimopan monohydrate has selectivity for μ-opioidreceptor (Ki=0.47 nM) over κ- and δ-opioidreceptors (Kis=100, 12 nM, respectively). Alvimopan monohydrate can be used for the research of postoperative ileus .
β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioidreceptor, with preferred affinity for μ-opioidreceptor and δ-opioidreceptor; β-Endorphin, human exhibits antinociception activity.
Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioidreceptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioidreceptor (Ki=0.47 nM) over κ- and δ-opioidreceptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus .
BMS-986121 is a positive allosteric modulator (PAM) of the μopioidreceptor extracted from patent WO2014107344. BMS-986121 is built on a chemical scaffold representing a new chemotype for μreceptor PAMs .
CYM51010 is a biased ligand of μ-opioidreceptor – δ-opioidreceptor heterodimers with an EC50 of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .
Valorphin is an endogenous hemoglobin β-chain (33-39) fragment with opioid analgesic activity, binds to rat mu-opioidreceptor, with an IC50 of 14 nM; Valorphin also shows anti-tumor activity.
DALDA acetate is a potent and highly selective μ-opioidreceptor agonist with a Ki of 1.69 nM. DALDA acetate shows antinociceptive and respiratory effects .
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioidreceptor (KOR) agonist, and is also an agonist for other opioidreceptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .
Naloxonazine dihydrochloride is a specific μ-opioidreceptor antagonist with an IC50 of 5.4 nM. Naloxonazine dihydrochloride also shows anti-leishmanial activity .
Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioidreceptor (KOR) agonist, and is also an agonist for other opioidreceptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .
β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioidreceptors. β-Endorphin, equine TFA has analgesic properties .
Sinomenine hydrochloride (Cucoline hydrochloride), an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation . Sinomenine also is an activator of μ-opioidreceptor .
DPI-3290 (Org 41793) is a potent and specific opioidreceptors agonist with Ki values of 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioidreceptors, respectively。DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity .
GSK1521498 is a potent and selective μ-opioidreceptor (MOR) antagonist. GSK1521498 has the potential for disorders of compulsive consumption of food, alcohol, and agents .
β-Endorphin, an endogenous opioid neuropeptide, is an opioidreceptor agonist. β-Endorphin binds preferentially to μ-opioidreceptors and is produced in certain neurons of the central and peripheral nervous system and is one of three endorphins produced in humans. β-Endorphin can be used to reduce stress and maintain homeostasis in the body and is involved in neurological pain perception regulation .
Naldemedine (S-297995) is an orally active μ-opioidreceptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioidreceptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
Naldemedine (S-297995) tosylate is an orally active μ-opioidreceptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioidreceptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
Endomorphin 2, a high affinity, highly selective agonist of the μ-opioidreceptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM.
CTAP is a potent, highly selective, and BBB penetrant μopioidreceptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
GSK1521498 free base is a potent and selective μ-opioidreceptor (MOR) antagonist. GSK1521498 free base has the potential for disorders of compulsive consumption of food, alcohol, and agents .
Endomorphin 2 TFA, a high affinity, highly selective agonist of the μ-opioidreceptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM .
GSK1521498 free base (hydrochloride) is a potent and selective μ-opioidreceptor (MOR) antagonist. GSK1521498 free base (hydrochloride) is being used for the treatment of disorders of compulsive consumption of food, alcohol, and agents .
CTAP TFA is a potent, highly selective, and BBB penetrant μopioidreceptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
AT-121 is a bifunctional nociception and muopioidreceptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .
AT-121 hydrochloride is a bifunctional nociception and muopioidreceptor agonist, with Kis of 3.67 and 16.49 nM, respectively. AT-121 hydrochloride is a safe, non-addictive analgesic, and shows antinociceptive and antiallodynic effects .
Speciociliatine-d3 is a deuterium labeled Speciociliatine. Speciociliatine is a alkaloid that can be isolated from Mitragyna speciosa. Speciociliatine is a μ-opioidreceptor partial agonist. Speciociliatine has orally active and antinociceptive activity .
Acetyl tetrapeptide-15 is a synthetic peptide used in the cosmetics for sensitive skin. Acetyl tetrapeptide-15 is derived from endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), a human μ-opioid agonist with selective anti-nociceptive effect. Acetyl tetrapeptide-15 reduces skin hyperreactivity producing inflammatory, chronic and neuropathic pain, by increasing the threshold of neuronal excitability in μ-opioidreceptor via an endorphin-like pathway .
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioidreceptors. UFP-101 shows antidepressant-like effect .
KNT-127 is a potent and selective δ-opioidreceptor agonist effective by systemic administration. KNT-127 shows selectivity for the δ-receptor (Ki 0f 21.3, 0.16, 153 nM for opioidμ-, δ-, and κ-receptors, respectively). KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex. Antidepressant-like effects .
MOR agonist-1 is a MOR (μ-opioidreceptor) agonist. MOR agonist-1 has good analgesic effect. MOR agonist-1 can be used for the research of pain and pain-related disorders .
Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioidreceptors. Trap-101 stimulates GTPγ 35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioidreceptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases .
β-Endorphin (1-27) (human) is an opioid antagonist that binds μ-, δ-, and κ-opioidreceptors with Kis of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .
Bilaid C, a tetrapeptide, can be isolated from the Australian estuarine isolate of Penicillium sp. MST-MF667. Bilaid C is also a potent and selective μ-OpioidReceptor (MOPr) agonist (Ki=210 nM, hMOPr) .
CTOP is a potent and highly selective μ-opioidreceptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
TAN-452 is an orally active, selective peripherally acting δ-opioidreceptor (DOR) antagonist with a Ki of 0.47 nM and a Kb of 0.21 nM. TAN-452 is an antagonist for μ-opioidreceptor (MOR; Ki=36.56 nM and Kb=9.43 nM) and κ-opioidreceptor (KOR; Ki=5.31 nM and Kb=7.18 nM). TAN-452, a derivative of Naltrindole, demonstrates low brain penetrability and attenuates morphine-induced side effects without affecting pain control .
BMS-986187 is an δ-opioidreceptor-selective positive allosteric modulator (PAM) with an EC50 of 0.03 μM and a pKB of 6.02 (∼1 μM). BMS-986187 has no observable PAM activity at the μ-receptor (EC50=3 μM) .
Endomorphin 1, a high affinity, highly selective agonist of the μ-opioidreceptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .
Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioidreceptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties .
BPR1M97 is a dual-acting muopioidreceptor (MOP) and nociceptin-orphanin FQ peptide (NOP) receptor agonist with Ki values of 1.8 and 4.2 nM, respectively. BPR1M97 shows high potency and blood-brain barrier penetration, and produces potent antinociceptive effects .
EST73502 is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioidreceptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 has antinociceptive activity .
UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pKi of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioidreceptors. UFP-101 TFA shows antidepressant-like effect .
BRL 52537 hydrochloride is a highly selective κ-Opioidreceptor (KOR) agonist with Kis of 0.24 nM and 1560 nM for κ and μ subtypes, respectively. BRL 52537 hydrochloride decreases ischemia-evoked NO production as a potential mechanism of neuroprotection. BRL 52537 hydrochloride attenuates early stroke damage .
EST73502 monohydrochloride is a selective, orally active and blood-brain barrier (BBB) penetrant dual μ-opioidreceptor (MOR) agonist and σ1 receptor (σ1R) antagonist, with Kis of 64 nM and 118 nM for MOR and σ1R, respectively. EST73502 monohydrochloride has antinociceptive activity .
LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappareceptors (Ki: 0.4 nM, 5.2, 2.0 nM respectively). LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity .
BU09059 is a potent and selective Kappa-opioidreceptor antagonist with a pA2 of 8.62. BU09059 has nanomolar affinity for the κ-receptor, with 15-fold and 616-fold selectivity over μ- and δ-receptors, respectively. BU09059 significantly blocks U50488 (HY-15997B)-induced antinociception .
[Arg14,Lys15]Nociceptin is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC50 of 1 nM. [Arg14,Lys15]Nociceptin displays high selectivity over opioidreceptors, with IC50s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .
MOR agonist-3 (Compound 84) is a D3R/MOR antagonist (Ki 382 nM and 55.2 nM respectively). MOR agonist-3 has the potential to produce analgesic effects through MOR (μ-opioidreceptor) (HY-149337) partial agonists and to reduce opioid abuse through D3R antagonists. MOR agonist-3 can be used in the treatment of inflammation and neuropathic pain research .
[Arg14,Lys15]Nociceptin TFA is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC50 of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioidreceptors, with IC50s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .
Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 µM. Corydaline is a μ-opioidreceptor (Ki of 1.23 µM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 µM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities .
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective NOP receptor (OP4) agonist, with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μopioidreceptors (>3000 fold) .
[(pF)Phe4]Nociceptin(1-13)NH2 TFA is a highly potent and selective NOP receptor (OP4) agonist, with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 TFA displays high selectivity over δ, κ, and μopioidreceptors (>3000 fold) .
BMS-986122 is a selective, potent positive allosteric modulator of the mu-opioidreceptor (µ-OR). BMS-986122 shows potentiation of orthosteric agonist-mediated β-arrestin recruitment, adenylyl cyclase inhibition, and G protein activation. BMS-986122 potentiates DAMGO-mediated [ 35S]GTPγS binding in mouse brain membranes .
SNC80 (NIH 10815) is a potent, highly selective and non-peptide δ-opioidreceptor agonist with a Ki of 1.78 nM and an IC50 of 2.73 nM. SNC80 also selectively activates μ-δ heteromer in HEK293 cells with an EC50 of 52.8 nM. SNC80 shows antinociceptive, antihyperalgesic and antidepressant‐like effects. SNC80 has the potential for multiple headache disorders treatment .
RS 39604 is a potent, selective, and orally active 5-HT4receptor antagonist with a pKi of 9.1 in guinea pig striatal membranes. RS 39604 displays a low affinity (pKi<6.5) for 5-HT1A, 5-HT2C, 5-HT3, α1c, D1, D2, M1, M2, AT1, B1 and opioidmureceptors and moderate affinity for δ1, (pKi=6.8) and δ2 (pKi=7.8) sites .
μ/κ/δ opioidreceptor agonist 1 is a μopioidreceptor (MOR), κ opioidreceptor (KOR), and δ opioidreceptor (DOR) agonist. μ/κ/δ opioidreceptor agonist 1 produces a strong and long-lasting analgesic effect through peripheral MOR and KOR in the tail-flick test .
Acetalin-1 (Ac-RFMWMK-NH2), a hexapeptide, is a μopioidreceptor antagonist with high affinity for μ and κ3 opioidreceptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .
PL-017 is a potent and selective μopioidreceptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 produces long-lasting, reversible analgesia in rats .
PL-017 TFA is a potent and selective μopioidreceptor agonist with an IC50 of 5.5 nM for 125I-FK 33,824 binding to μ site. PL-017 TFA produces long-lasting, reversible analgesia in rats .
Acetalin-3 (Ac-RFMWMT-NH2), a hexapeptide, is a μopioidreceptor antagonist with high affinity for μ and κ3 opioidreceptor, weak affinity for κ1 receptors and no affinity for κ2 receptors .
β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioidreceptor, with preferred affinity for μ-opioidreceptor and δ-opioidreceptor; β-Endorphin, human exhibits antinociception activity.
DALDA acetate is a potent and highly selective μ-opioidreceptor agonist with a Ki of 1.69 nM. DALDA acetate shows antinociceptive and respiratory effects .
Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioidreceptor (KOR) agonist, and is also an agonist for other opioidreceptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .
Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioidreceptor (KOR) agonist, and is also an agonist for other opioidreceptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .
β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioidreceptors. β-Endorphin, equine TFA has analgesic properties .
β-Endorphin, an endogenous opioid neuropeptide, is an opioidreceptor agonist. β-Endorphin binds preferentially to μ-opioidreceptors and is produced in certain neurons of the central and peripheral nervous system and is one of three endorphins produced in humans. β-Endorphin can be used to reduce stress and maintain homeostasis in the body and is involved in neurological pain perception regulation .
Endomorphin 2, a high affinity, highly selective agonist of the μ-opioidreceptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM.
CTAP is a potent, highly selective, and BBB penetrant μopioidreceptor antagonist, with an IC50 of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
Endomorphin 2 TFA, a high affinity, highly selective agonist of the μ-opioidreceptor, displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM .
CTAP TFA is a potent, highly selective, and BBB penetrant μopioidreceptor antagonist, with an IC50 of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC50=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .
Acetyl tetrapeptide-15 is a synthetic peptide used in the cosmetics for sensitive skin. Acetyl tetrapeptide-15 is derived from endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), a human μ-opioid agonist with selective anti-nociceptive effect. Acetyl tetrapeptide-15 reduces skin hyperreactivity producing inflammatory, chronic and neuropathic pain, by increasing the threshold of neuronal excitability in μ-opioidreceptor via an endorphin-like pathway .
UFP-101 is a potent, selective, and competitive antagonist of the NOP receptor, with a pKi of 10.24. UFP-101 displays >3000-fold selectivity over δ, μ and κ opioidreceptors. UFP-101 shows antidepressant-like effect .
β-Endorphin (1-27) (human) is an opioid antagonist that binds μ-, δ-, and κ-opioidreceptors with Kis of 5.31, 6.17, and 39.82 nM, respectively. β-Endorphin (1-27) (human) inhibits β-Endorphin (HY-P1502)-induced and etorphine-induced analgesia .
Bilaid C, a tetrapeptide, can be isolated from the Australian estuarine isolate of Penicillium sp. MST-MF667. Bilaid C is also a potent and selective μ-OpioidReceptor (MOPr) agonist (Ki=210 nM, hMOPr) .
CTOP is a potent and highly selective μ-opioidreceptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
Endomorphin 1, a high affinity, highly selective agonist of the μ-opioidreceptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .
Endomorphin 1 acetate, a high affinity, highly selective agonist of the μ-opioidreceptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 acetate has antinociceptive properties .
UFP-101 TFA is a potent, selective, and competitive antagonist of the N/OFQ peptide (NOP) receptor, with a pKi of 10.24. UFP-101 TFA displays >3000-fold selectivity over δ, μ and κ opioidreceptors. UFP-101 TFA shows antidepressant-like effect .
[Arg14,Lys15]Nociceptin is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC50 of 1 nM. [Arg14,Lys15]Nociceptin displays high selectivity over opioidreceptors, with IC50s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .
[Arg14,Lys15]Nociceptin TFA is a highly potent and selective NOP receptor (ORL1; OP4) agonist, with an EC50 of 1 nM. [Arg14,Lys15]Nociceptin TFA displays high selectivity over opioidreceptors, with IC50s of 0.32, 280, >10000 and 1500 nM for NOP, μ, δ and κ receptors, respectively .
[(pF)Phe4]Nociceptin(1-13)NH2 is a highly potent and selective NOP receptor (OP4) agonist, with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 displays high selectivity over δ, κ, and μopioidreceptors (>3000 fold) .
β-Endorphin, equine TFA is an endogenous opioid peptide, which binds at high affinity to both μ/δ opioidreceptors. β-Endorphin, equine TFA has analgesic properties .
Sinomenine hydrochloride (Cucoline hydrochloride), an alkaloid extracted from Sinomenium acutum, is a blocker of the NF-κB activation . Sinomenine also is an activator of μ-opioidreceptor .
Endomorphin 1, a high affinity, highly selective agonist of the μ-opioidreceptor (Ki: 1.11 nM), displays reasonable affinities for kappa3 binding sites, with Ki value between 20 and 30 nM. Endomorphin 1 has antinociceptive properties .
Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 µM. Corydaline is a μ-opioidreceptor (Ki of 1.23 µM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 µM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities .
The OPRM1 protein serves as a receptor for endogenous and synthetic opioids and undergoes conformational changes upon agonist binding, activating downstream signaling pathways. This includes coupling to G proteins, thereby regulating adenylyl cyclase, calcium channels, potassium channels, and intracellular signaling pathways. OPRM1 Protein, Human (Cell-Free, His) is the recombinant human-derived OPRM1 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of OPRM1 Protein, Human (Cell-Free, His) is 400 a.a., with molecular weight of 47.6 kDa.
Naloxegol-d5 (oxalate) is deuterium labeled Naloxegol (oxalate). Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is a μ-opioid-receptor antagonist. Naloxegol oxalate inhibits opioid binding in μ-opioidreceptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation[1][2].
Speciociliatine-d3 is a deuterium labeled Speciociliatine. Speciociliatine is a alkaloid that can be isolated from Mitragyna speciosa. Speciociliatine is a μ-opioidreceptor partial agonist. Speciociliatine has orally active and antinociceptive activity .
Inquiry Online
Your information is safe with us. * Required Fields.